| pubmed-article:16195627 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16195627 | lifeskim:mentions | umls-concept:C0003842 | lld:lifeskim |
| pubmed-article:16195627 | lifeskim:mentions | umls-concept:C0221198 | lld:lifeskim |
| pubmed-article:16195627 | lifeskim:mentions | umls-concept:C0055729 | lld:lifeskim |
| pubmed-article:16195627 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:16195627 | lifeskim:mentions | umls-concept:C2936666 | lld:lifeskim |
| pubmed-article:16195627 | lifeskim:mentions | umls-concept:C0581603 | lld:lifeskim |
| pubmed-article:16195627 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:16195627 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:16195627 | pubmed:dateCreated | 2005-9-30 | lld:pubmed |
| pubmed-article:16195627 | pubmed:abstractText | Although percutaneous transluminal angioplasty (PTA) is being widely used for the treatment of stenosis of peripheral arteries, the high in-stent restenosis rate (50-60%) in the femoropopliteal artery still remains an unsolved issue. Cilostazol is a unique antiplatelet drug that has vasodilatory effects and inhibits smooth muscle cell proliferation. | lld:pubmed |
| pubmed-article:16195627 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16195627 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16195627 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16195627 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16195627 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16195627 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16195627 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16195627 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:16195627 | pubmed:issn | 1346-9843 | lld:pubmed |
| pubmed-article:16195627 | pubmed:author | pubmed-author:KitakazeMasaf... | lld:pubmed |
| pubmed-article:16195627 | pubmed:author | pubmed-author:MinamiguchiHi... | lld:pubmed |
| pubmed-article:16195627 | pubmed:author | pubmed-author:IidaOsamuO | lld:pubmed |
| pubmed-article:16195627 | pubmed:author | pubmed-author:UematsuMasaak... | lld:pubmed |
| pubmed-article:16195627 | pubmed:author | pubmed-author:NantoShinsuke... | lld:pubmed |
| pubmed-article:16195627 | pubmed:author | pubmed-author:MorozumiTakak... | lld:pubmed |
| pubmed-article:16195627 | pubmed:author | pubmed-author:NagataSeikiS | lld:pubmed |
| pubmed-article:16195627 | pubmed:author | pubmed-author:AwataMasakiM | lld:pubmed |
| pubmed-article:16195627 | pubmed:author | pubmed-author:KotaniJun-Ich... | lld:pubmed |
| pubmed-article:16195627 | pubmed:author | pubmed-author:OnishiToshina... | lld:pubmed |
| pubmed-article:16195627 | pubmed:author | pubmed-author:ItoNoriakiN | lld:pubmed |
| pubmed-article:16195627 | pubmed:author | pubmed-author:OshimaFusakoF | lld:pubmed |
| pubmed-article:16195627 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16195627 | pubmed:volume | 69 | lld:pubmed |
| pubmed-article:16195627 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16195627 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16195627 | pubmed:pagination | 1256-9 | lld:pubmed |
| pubmed-article:16195627 | pubmed:meshHeading | pubmed-meshheading:16195627... | lld:pubmed |
| pubmed-article:16195627 | pubmed:meshHeading | pubmed-meshheading:16195627... | lld:pubmed |
| pubmed-article:16195627 | pubmed:meshHeading | pubmed-meshheading:16195627... | lld:pubmed |
| pubmed-article:16195627 | pubmed:meshHeading | pubmed-meshheading:16195627... | lld:pubmed |
| pubmed-article:16195627 | pubmed:meshHeading | pubmed-meshheading:16195627... | lld:pubmed |
| pubmed-article:16195627 | pubmed:meshHeading | pubmed-meshheading:16195627... | lld:pubmed |
| pubmed-article:16195627 | pubmed:meshHeading | pubmed-meshheading:16195627... | lld:pubmed |
| pubmed-article:16195627 | pubmed:meshHeading | pubmed-meshheading:16195627... | lld:pubmed |
| pubmed-article:16195627 | pubmed:meshHeading | pubmed-meshheading:16195627... | lld:pubmed |
| pubmed-article:16195627 | pubmed:meshHeading | pubmed-meshheading:16195627... | lld:pubmed |
| pubmed-article:16195627 | pubmed:meshHeading | pubmed-meshheading:16195627... | lld:pubmed |
| pubmed-article:16195627 | pubmed:meshHeading | pubmed-meshheading:16195627... | lld:pubmed |
| pubmed-article:16195627 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16195627 | pubmed:articleTitle | Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. | lld:pubmed |
| pubmed-article:16195627 | pubmed:affiliation | Kansai Rosai Hospital, Amagasaki, Japan. osa-iida@nifty.com | lld:pubmed |
| pubmed-article:16195627 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16195627 | lld:pubmed |
